GURUFOCUS.COM » STOCK LIST » USA » NAS » OncoCyte Corp (NAS:OCX) » Definitions » Return-on-Tangible-Asset
Switch to:

OncoCyte (NAS:OCX) Return-on-Tangible-Asset

: -65.89% (As of Sep. 2022)
View and export this data going back to 2015. Start your Free Trial

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. OncoCyte's annualized Net Income for the quarter that ended in Sep. 2022 was $-37.33 Mil. OncoCyte's average total tangible assets for the quarter that ended in Sep. 2022 was $56.66 Mil. Therefore, OncoCyte's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2022 was -65.89%.

The historical rank and industry rank for OncoCyte's Return-on-Tangible-Asset or its related term are showing as below:

OCX' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -169   Med: -96.42   Max: -53.17
Current: -123.94

During the past 9 years, OncoCyte's highest Return-on-Tangible-Asset was -53.17%. The lowest was -169.00%. And the median was -96.42%.

OCX's Return-on-Tangible-Asset is ranked worse than
87.98% of 1581 companies
in the Biotechnology industry
Industry Median: -38.07 vs OCX: -123.94

OncoCyte Return-on-Tangible-Asset Historical Data

The historical data trend for OncoCyte's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Return-on-Tangible-Asset
Premium Member Only Premium Member Only Premium Member Only Premium Member Only -169.00 -165.94 -90.84 -84.22 -158.54

OncoCyte Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Return-on-Tangible-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -94.67 -268.75 -94.73 -66.20 -65.89

Competitive Comparison

For the Biotechnology subindustry, OncoCyte's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

OncoCyte Return-on-Tangible-Asset Distribution

For the Biotechnology industry and Healthcare sector, OncoCyte's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where OncoCyte's Return-on-Tangible-Asset falls in comparison to its industry or sector. The grey bar indicates the Return-on-Tangible-Asset's extreme value range as defined by GuruFocus.



OncoCyte Return-on-Tangible-Asset Calculation

OncoCyte's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2021 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2021 )  (A: Dec. 2020 )(A: Dec. 2021 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2021 )  (A: Dec. 2020 )(A: Dec. 2021 )
=-64.097/( (31.223+49.634)/ 2 )
=-64.097/40.4285
=-158.54 %

OncoCyte's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2022 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Sep. 2022 )  (Q: Jun. 2022 )(Q: Sep. 2022 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Sep. 2022 )  (Q: Jun. 2022 )(Q: Sep. 2022 )
=-37.332/( (63.026+50.295)/ 2 )
=-37.332/56.6605
=-65.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2022) net income data.


OncoCyte  (NAS:OCX) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


OncoCyte Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of OncoCyte's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoCyte (NAS:OCX) Business Description

OncoCyte logo
Traded in Other Exchanges
Address
15 Cushing, Irvine, CA, USA, 92618
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.
Executives
Paulsen Gisela officer: Chief Operating Officer 5505 ENDEAVOR LANE MADISON WI 53719
Yu Li officer: VP Cntrllr/Prncpl Acctng Offcr 120 NEWPORT CENTER DRIVE. NEWPORT BEACH CA 92660
Carter Jennifer L. director C/O DFP SPONSOR LLC 780 THIRD AVENUE, 37TH FLOOR NEW YORK NY 10017
Ross Douglas T. officer: Chief Medical Officer 15 CUSHING IRVINE CA 92618
Kamen Efrem 10 percent owner C/O PURA VIDA INVESTMENTS, LLC 512 W 22ND STREET, 7TH FLOOR NEW YORK NY 10011
Pura Vida Investments, Llc 10 percent owner 512 W 22ND STREET 7TH FLOOR NEW YORK NY 10011
Kalajian Tony T officer: SVP-Chief Accounting Officer 1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501
Griffith Melinda director 1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501
Sundar Padma officer: SVP, Marketing & Market Access 1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501
Andrews Ronald Asbury director 5791 VAN ALLEN WAY CARLSBAD CA 92008
Parker Albert P officer: Chief Operating Officer C/O ONCOCYTE CORPORATION 1010 ATLANTIC AVENUE, SUITE 102 ALAMEDA CA 94501
Levine Mitchell S officer: Chief Financial Officer ONE FERRY BUILDING, SUITE 255 SAN FRANCISCO CA 94111
Hesterberg Lyndal K. officer: Sr VP, Research & Development 1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501
Bailey Don M director 1300 N. KELLOGG DRIVE SUITE D ANAHEIM CA 92607
Bradsher Neal C 10 percent owner

OncoCyte (NAS:OCX) Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
premium membership